CR11249A - Formulaciones de anticuerpos - Google Patents

Formulaciones de anticuerpos

Info

Publication number
CR11249A
CR11249A CR11249A CR11249A CR11249A CR 11249 A CR11249 A CR 11249A CR 11249 A CR11249 A CR 11249A CR 11249 A CR11249 A CR 11249A CR 11249 A CR11249 A CR 11249A
Authority
CR
Costa Rica
Prior art keywords
formulations
antibodies
stable
nacl
citrate
Prior art date
Application number
CR11249A
Other languages
English (en)
Inventor
E Brisbane Charlene
Sharad Ketkar Amol
Tove Lashmar Ulla
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40228991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CR11249A publication Critical patent/CR11249A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Esta invencion se refiere a formulaciones de anticuerpo estables a la temperatura y la cizalladura que son mas estables comparadas con una formulacion estandar (tal como citrato 30 mM, NaCl 100 mM, pH 6,5).
CR11249A 2007-07-06 2010-02-02 Formulaciones de anticuerpos CR11249A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94822007P 2007-07-06 2007-07-06

Publications (1)

Publication Number Publication Date
CR11249A true CR11249A (es) 2010-03-08

Family

ID=40228991

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11249A CR11249A (es) 2007-07-06 2010-02-02 Formulaciones de anticuerpos

Country Status (38)

Country Link
US (2) US20110020328A1 (es)
EP (2) EP2170388B1 (es)
JP (1) JP5529017B2 (es)
KR (2) KR101670454B1 (es)
CN (1) CN101820912B (es)
AR (2) AR067455A1 (es)
AU (1) AU2008275278B2 (es)
BR (2) BR122020026978B1 (es)
CA (1) CA2692681C (es)
CL (1) CL2008001984A1 (es)
CO (1) CO6270340A2 (es)
CR (1) CR11249A (es)
CY (2) CY1118419T1 (es)
DK (2) DK2889310T3 (es)
DO (1) DOP2010000001A (es)
EA (1) EA017994B1 (es)
ES (2) ES2663504T3 (es)
FR (1) FR21C1040I1 (es)
HK (2) HK1207652A1 (es)
HR (2) HRP20170033T1 (es)
HU (3) HUE038501T2 (es)
IL (1) IL202950A (es)
JO (1) JO3219B1 (es)
LT (3) LT2889310T (es)
MA (1) MA31471B1 (es)
MX (1) MX2010000017A (es)
NO (2) NO2889310T3 (es)
NZ (1) NZ582250A (es)
PE (1) PE20090738A1 (es)
PL (2) PL2170388T3 (es)
PT (2) PT2889310T (es)
SI (2) SI2170388T1 (es)
TR (1) TR201802928T4 (es)
TW (2) TWI612060B (es)
UA (1) UA107557C2 (es)
UY (1) UY31210A1 (es)
WO (1) WO2009009407A1 (es)
ZA (1) ZA200909107B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
CA3101298A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
AU2012243126A1 (en) * 2011-04-07 2013-10-17 Glaxosmithkline Llc Formulations with reduced viscosity
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
ES2899756T3 (es) 2013-03-12 2022-03-14 Primal Therapies Inc Composición dental que comprende quelante y base
EP2805730A1 (en) * 2013-05-21 2014-11-26 Bergen Teknologioverforing AS Nitric oxide donor for the treatment of chronic fatigue syndrome
WO2015162504A1 (en) 2014-04-23 2015-10-29 Novartis Ag Novel dosing and uses of ofatumumab
WO2016189491A1 (en) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Novel formulation
AU2017213775A1 (en) * 2016-02-03 2018-08-16 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
KR20200136503A (ko) 2016-08-15 2020-12-07 노파르티스 아게 오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법
JPWO2018179138A1 (ja) * 2017-03-29 2020-02-06 持田製薬株式会社 抗体含有液体製剤
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11513046B2 (en) * 2018-02-09 2022-11-29 Championx Usa Inc. Flowability testing systems and methods
CN114375306A (zh) 2019-09-11 2022-04-19 诺华股份有限公司 奥法木单抗治疗患者中除多发性硬化症以外病症的管理
EP3864053B1 (en) 2019-09-11 2023-07-05 Novartis AG Treatment of rms by switching therapy
CN112675126A (zh) * 2019-10-18 2021-04-20 百奥泰生物制药股份有限公司 抗cd20抗体制剂及其应用
WO2021204994A1 (en) 2020-04-09 2021-10-14 Novartis Ag Ofatumumab for treating ms while maintaining serum igg
JP7057954B2 (ja) * 2020-09-03 2022-04-21 国立大学法人大阪大学 改善された保存安定性を有するタンパク質含有液体製剤
CN117529336A (zh) 2021-04-14 2024-02-06 诺华股份有限公司 用于治疗亚洲患者的多发性硬化症的奥法木单抗
IL310813A (en) 2021-08-16 2024-04-01 Novartis Ag OFATUMUMAB for the treatment of multiple sclerosis in children
KR20230150203A (ko) * 2022-04-20 2023-10-30 주식회사 알토스바이오로직스 오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
DE69810481T2 (de) * 1997-06-13 2003-09-25 Genentech Inc Stabilisierte antikörperformulierung
PT1491208E (pt) * 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1519959B1 (en) 2002-02-14 2014-04-02 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
AU2003219958B2 (en) * 2002-02-27 2006-01-05 Immunex Corporation Polypeptide formulation
NZ537687A (en) * 2002-06-21 2008-04-30 Biogen Idec Inc Buffered formulations for concentrating antibodies and methods of use thereof
WO2004035607A2 (en) * 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
ATE527278T1 (de) * 2002-12-16 2011-10-15 Genmab As Humane monoklonale antikörper gegen interleukin 8 (il-8)
US8084582B2 (en) * 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US20090238820A1 (en) * 2005-03-08 2009-09-24 Allan Corey M ANTI-MAdCAM ANTIBODY COMPOSITIONS
KR101363777B1 (ko) * 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―１３ 항체 조성물
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS

Also Published As

Publication number Publication date
HUE031288T2 (hu) 2017-06-28
KR20150088335A (ko) 2015-07-31
DOP2010000001A (es) 2010-01-31
TR201802928T4 (tr) 2018-03-21
EP2889310B1 (en) 2017-12-20
EA017994B1 (ru) 2013-04-30
WO2009009407A1 (en) 2009-01-15
JP2011526880A (ja) 2011-10-20
MA31471B1 (fr) 2010-06-01
EA201070105A1 (ru) 2010-08-30
LTPA2021520I1 (es) 2021-10-11
JO3219B1 (ar) 2018-03-08
ZA200909107B (en) 2012-12-27
EP2170388A1 (en) 2010-04-07
AU2008275278A1 (en) 2009-01-15
NO2889310T3 (es) 2018-05-19
PE20090738A1 (es) 2009-07-18
CN101820912A (zh) 2010-09-01
CY1118419T1 (el) 2017-06-28
BRPI0814003B1 (pt) 2021-06-15
AU2008275278B2 (en) 2011-04-14
PL2170388T3 (pl) 2017-06-30
AR067455A1 (es) 2009-10-14
NZ582250A (en) 2012-04-27
HRP20170033T1 (hr) 2017-03-24
CN101820912B (zh) 2014-03-12
EP2170388A4 (en) 2011-07-06
BRPI0814003A2 (pt) 2015-02-03
CY1120047T1 (el) 2018-12-12
US20150158951A1 (en) 2015-06-11
LT2170388T (lt) 2017-01-10
SI2889310T1 (en) 2018-04-30
HK1141979A1 (zh) 2010-11-26
HUS2100038I1 (hu) 2021-10-28
EP2889310A1 (en) 2015-07-01
BR122020026978B1 (pt) 2021-09-28
SI2170388T1 (sl) 2017-01-31
TW200914466A (en) 2009-04-01
MX2010000017A (es) 2010-04-07
KR20100038092A (ko) 2010-04-12
LT2889310T (lt) 2018-03-26
PT2889310T (pt) 2018-03-26
US20110020328A1 (en) 2011-01-27
UA107557C2 (xx) 2015-01-26
TWI515204B (zh) 2016-01-01
TWI612060B (zh) 2018-01-21
NO2021036I1 (no) 2021-09-13
CA2692681C (en) 2018-12-04
HUE038501T2 (hu) 2018-10-29
TW201623334A (zh) 2016-07-01
CA2692681A1 (en) 2009-01-15
FR21C1040I1 (fr) 2021-11-19
CO6270340A2 (es) 2011-04-20
HRP20180440T1 (hr) 2018-04-20
ES2610821T3 (es) 2017-05-03
DK2170388T3 (en) 2017-01-16
IL202950A (en) 2014-05-28
JP5529017B2 (ja) 2014-06-25
PT2170388T (pt) 2017-01-04
KR101670454B1 (ko) 2016-10-31
ES2663504T3 (es) 2018-04-13
HK1207652A1 (en) 2016-02-19
CL2008001984A1 (es) 2009-01-09
UY31210A1 (es) 2009-01-30
IL202950A0 (en) 2011-08-01
AR109461A2 (es) 2018-12-12
DK2889310T3 (en) 2018-03-26
PL2889310T3 (pl) 2018-06-29
EP2170388B1 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
CR11249A (es) Formulaciones de anticuerpos
CR10444A (es) Anticuerpo humanizado de c-kit
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
PA8671301A1 (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricación y utilización
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
CY1114769T1 (el) Διασπαρσιμα στο νερο αγροχημικα σκευασματα που αποτελουνται απο πολυαλκοξυτριγλυκεριδια ως υποκινητες διεισδυσης
HN2008001191A (es) Compuestos de biciclolactama sustituida
PA8650801A1 (es) Composiciones y formulaciones de ecteinascidina, como la ecteinascidina 743
GT200600383A (es) Formulaciones de acetato de bazedoxifeno
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
CO6571886A2 (es) Antagonistas de pcsk9
CR9821A (es) Metodos y composiciones para el control genetico de infestaciones de insectos en plantas
ECSP11011246A (es) Métodos para reducir la proliferación y viabilidad de los agentes microbianos
PA8625201A1 (es) Composiciones de peróxido estabilizadas
GT200900027A (es) Compuestos organicos
GT200500357A (es) Indazoles substituidos, composicones que los comprenden, procedimiento de su preparacion y utilizacion
CR11007A (es) Formulaciones estables de de acido s-(+)- abscisico liquidas y de granulo soluble
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
UY29478A1 (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
DK1978823T3 (da) Sammensætninger og fremgangsmåde til at fremme fedttab
UY30534A1 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapéutica como antagonistas de los receptores de urotensina ii
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
EA200970472A1 (ru) Замещенные пиразолы, композиции, их содержащие, способ получения и применение